The Role of Cannabinoid Receptor Type 2 in the Bone Loss Associated With Pediatric Celiac Disease
Conclusions:
CB2 could be a molecular marker to predict the risk of bone alterations in CD and a pharmacological target to reduce bone mass loss in patients who need a direct intervention on bone metabolism, in addition to the GFD.
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Article: Gastroenterology: Celiac Disease Source Type: research
More News: Celiac Disease | Children | Coeliac Disease | Diets | Gastroenterology | Gluten | Nutrition | Pediatrics | Study | Vitamin D | Vitamins